2023
Appearance of tolerance-induction and non-inflammatory SARS-CoV-2 spike-specific IgG4 antibodies after COVID-19 booster vaccinations
Akhtar M, Islam M, Khaton F, Soltana U, Jafrin S, Rahman S, Tauheed I, Ahmed T, Khan I, Akter A, Khan Z, Islam M, Khanam F, Biswas P, Ahmmed F, Ahmed S, Rashid M, Hossain M, Alam A, Alamgir A, Rahman M, Ryan E, Harris J, LaRocque R, Flora M, Chowdhury F, Khan A, Banu S, Shirin T, Bhuiyan T, Qadri F. Appearance of tolerance-induction and non-inflammatory SARS-CoV-2 spike-specific IgG4 antibodies after COVID-19 booster vaccinations. Frontiers In Immunology 2023, 14: 1309997. PMID: 38173725, PMCID: PMC10763240, DOI: 10.3389/fimmu.2023.1309997.Peer-Reviewed Original ResearchConceptsFuture vaccination strategiesIgG responsesVaccination strategiesVaccine typesImmunological toleranceImmune responseMRNA dosesSpecific IgG antibody responseIgG subclass analysisRobust IgG responseChAdOx1 nCoV-19IgG antibody responsePrimary IgG responseSARS-CoV-2 variantsHumoral immune responseMRNA vaccine dosesCOVID-19 vaccinationNumber of dosesSARS-CoV-2 spike receptorBooster dosesBooster vaccinationIgG4 levelsIgG4 responsesMRNA vaccinationIgG levels
2006
Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I.
HILL D, BAIRD J, PARISE M, LEWIS L, RYAN E, MAGILL A. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. American Journal Of Tropical Medicine And Hygiene 2006, 75: 402-15. PMID: 16968913, DOI: 10.4269/ajtmh.2006.75.402.Peer-Reviewed Original ResearchConceptsP. ovale malariaPrimary prophylaxisAdult doseRelapses of Plasmodium vivaxAnti-relapse therapyRecommended adult doseMalaria speciesP. vivaxPlasmodium vivaxBlood schizonticideDeficiency of G6PDLiver stagesMalarious regionsRadical cureEstablished infectionPrevent relapseClinical trialsMalariaProphylaxisPrimaquineDosePrimaquine phosphateGlucose-6-phosphate dehydrogenaseDaysGlucose-6-phosphate